HepB-CpG Vaccine Is Superior to HepB-alum in People With HIV and Prior Vaccine Nonresponse: A5379
Background: Conventional Hepatitis B surface antigen (HBsAg)-based vaccines achieve seroprotection response (SPR, HBsAb≥10 mIU/mL) in 35-80% of people with HIV (PWH) with 3 doses. HepB-CpG (vaccine with a TLR-9 agonist adjuvant) achieves high SPR in PWH, but limited data exist for non-responders to conventional vaccines. Methods: ACTG A5379 is an ongoing, open-label study to evaluate…